Information Provided By: 
Fly News Breaks for September 20, 2018
TTPH
Sep 20, 2018 | 18:10 EDT
Piper Jaffray analyst Edward Tenthoff kept his Overweight rating and $8 price target on Tetraphase after its expected approval of XERAVA for the treatment of complicated intra-abdominal infections with a broad label. The analyst sees the label allowing the use of XERAVA as a "broad-spectrum antibiotic", which he says speaks to the strength of the Phase III data. Tenthoff anticipates the drug to be launched in the U.S. after IDWeek in October and in Europe during early 2019.
News For TTPH From the Last 2 Days
There are no results for your query TTPH
